Francesca Calderon

Hematology | Oncology
450 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL.

Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL.

Journal: Blood advances
Published: March 11, 2026

PTPN2 Deletion Enhances CAR-T Effector Function and CNS Trafficking in a Non-Human Primate Model.

PTPN2 Deletion Enhances CAR-T Effector Function and CNS Trafficking in a Non-Human Primate Model.

Journal: Blood advances
Published: January 15, 2026

PTPN2-KO CAR-T Cells Demonstrate Enhanced Effector Function, CNS Infiltration, and Toxicity in a Non-Human Primate CAR-T Model.

PTPN2-KO CAR-T Cells Demonstrate Enhanced Effector Function, CNS Infiltration, and Toxicity in a Non-Human Primate CAR-T Model.

Journal: bioRxiv : the preprint server for biology
Published: September 26, 2025

Precision Editing of Cyclophilin A Generates Cyclosporine and Voclosporin Resistant Cellular Therapies.

Precision Editing of Cyclophilin A Generates Cyclosporine and Voclosporin Resistant Cellular Therapies.

Journal: bioRxiv : the preprint server for biology
Published: July 14, 2025

KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma.

KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma.

Journal: bioRxiv : the preprint server for biology
Published: July 09, 2025

Umbilical Cord Blood Reduced Relapse but Increased Nonrelapse Mortality Compared to Matched Unrelated Donor Transplantation in Pediatric Acute Myeloid Leukemia With Active Disease: A CIBMTR 2008 to 2017 Analysis of Donor Source and Residual Disease.

Umbilical Cord Blood Reduced Relapse but Increased Nonrelapse Mortality Compared to Matched Unrelated Donor Transplantation in Pediatric Acute Myeloid Leukemia With Active Disease: A CIBMTR 2008 to 2017 Analysis of Donor Source and Residual Disease.

Journal: Transplantation and cellular therapy
Published: November 22, 2024

Human OX40L-CAR-Tregs target activated antigen-presenting cells and control T cell alloreactivity.

Human OX40L-CAR-Tregs target activated antigen-presenting cells and control T cell alloreactivity.

Journal: Science translational medicine
Published: October 16, 2024

Outpatient Management of Fever and Neutropenia in Low-risk Children with Solid Tumors: A Quality Improvement Initiative.

Outpatient Management of Fever and Neutropenia in Low-risk Children with Solid Tumors: A Quality Improvement Initiative.

Journal: Pediatric quality & safety
Published: April 19, 2024

Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate-conditioned Fanconi anemia mice.

Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate-conditioned Fanconi anemia mice.

Journal: Blood
Published: December 07, 2023

B-cell-directed CAR T-cell therapy activates CD8+ cytotoxic CARneg bystander T cells in patients and nonhuman primates.

B-cell-directed CAR T-cell therapy activates CD8+ cytotoxic CARneg bystander T cells in patients and nonhuman primates.

Journal: Blood
Published: October 19, 2023

Targeting of the CD161 inhibitory receptor enhances T-cell-mediated immunity against hematological malignancies.

Targeting of the CD161 inhibitory receptor enhances T-cell-mediated immunity against hematological malignancies.

Journal: Blood
Published: October 12, 2023

Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease.

Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease.

Journal: Blood advances
Published: March 29, 2023
Showing 1-12 of 18

Last Updated: 09/26/2026